Here are the 424B prospectus supplements from Dianthus Therapeutics, Inc. (DNTH) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow DNTH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DNTH filings page.
Dianthus Therapeutics is offering 7,313,582 shares of common stock and pre-funded warrants to purchase 402,468 shares of common stock at a public offering price of $81.00 per share. The offering is subject to an underwriters’ option to purchase up to an additional 1,157,407 shares.
Delivery is expected on March 12, 2026. Net proceeds are estimated at approximately $585.4 million (or approximately $673.5 million if the underwriters’ option is exercised in full). Proceeds are intended to advance clinical and preclinical development, commercial readiness, working capital and general corporate purposes; management will have broad discretion over use.
Dianthus Therapeutics filed a preliminary prospectus supplement to offer $400,000,000 of common stock and, in lieu of shares for certain investors, pre-funded warrants to purchase common stock. The offering includes an underwriter option to purchase up to an additional $60,000,000.
The company’s common stock trades on Nasdaq under the symbol DNTH; the prospectus cites a reported sale price of $65.20 per share as of March 6, 2026. The prospectus states pro forma shares outstanding of 43,223,090 as of December 31, 2025. Net proceeds are intended to fund clinical and preclinical development, commercial readiness, working capital and general corporate purposes; management estimates cash will fund operations into late 2029.